Incannex Healthcare Inc.

IXHL

Healthcare Drug Manufacturers Specialty & Generic

Incannex Healthcare Inc.’s revenue for fiscal 2025 (year ended June 2025) was $86,000.00, up 616.7% from fiscal 2024.

Revenue
−92.3%
EPS
+98.6%
Free cash flow
+327.7%

Quarter to June 2026, against a year earlier

2.24 0.03 −1.32%
Market cap
$28.1M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
3/9
ROIC
0.00%
Net debt / EBITDA
3.0×
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
47.51 48.27 41.56 48.81
Net Debt/EBITDA
10.89 9.98 18.69 13.17
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.89) (0.40) (0.20) 0.29
Book value per Share
7.45 6.31 6.09 5.78
Free Cash Flow
(9.16) (4.63) (2.46) 3.38
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026